CJC-1295 No DAC 5 mg + Ipamorelin 5 mg

CJC-1295 No DAC 5 mg + Ipamorelin 5 mg is a dual-peptide formulation designed for growth hormone and endocrine signaling research, combining two research peptides with distinct receptor-related mechanisms.

CJC-1295 No DAC, commonly used in the research-peptide field to refer to Modified GRF (1-29), is a short-acting GHRH analog investigated for GHRH receptor activation, pituitary function, GH release, and pulsatile growth hormone signaling.

Ipamorelin is a growth-hormone-secretagogue-related research peptide studied for its interaction with the ghrelin receptor/GHS-R1a (Growth Hormone Secretagogue Receptor) and associated pituitary GH-release mechanisms.

Together, the two compounds provide an experimental system for investigating interactions between GHRH receptor and GHS-R1a signaling, including their relationships with pulsatile GH secretion, the GH/IGF-1 axis, and endocrine regulation.

The safety, efficacy, or appropriate human dosing of this specific 5 mg + 5 mg combination cannot be inferred from studies of either component individually and should not be represented as having established muscle-building, fat-loss, anti-aging, or performance-enhancing effects.

Envío estándar gratis en pedidos superiores a 50 $ a EE. UU., Canadá, México y Europa. Los pedidos salen en 1 día laborable.

¿No te convence? Devuélvelo en 30 días y te reembolsamos el importe completo, aunque esté abierto.